[299 Pages Report] The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7 billion in 2021, at a CAGR of 12.4% during the forecast period. The market is primarily driven by the prevalence of cancer and other target diseases. The development of therapies for key diseases, such as cancer, has attracted significant attention.
Furthermore, increasing investments of pharmaceutical companies in the development of novel drugs is also fueling the market growth. However, significant operational costs are expected to negatively impact the cell & gene therapy manufacturing market thus limiting the growth.
The pandemic slowed the economic growth of various countries, including the US, Germany, the UK, India, and China. It also resulted in control measures that impacted operations in life science organizations, such as production and research. In an article published by Nature Biotechnology, the CEO of Flagship Pioneering (US) stated that lab productivity at many of its research-based setups was running at just 30–50% capacity, and even upholding that rate was a challenge.
For More Info, Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=180609441
More than 750 trials of cell & gene therapy (CGT) in almost 30,000 patients were underway as of June 2020, and CGT products account for some 12% of the pharmaceutical industry’s clinical pipeline and at least 16% of its preclinical pipeline. According to GEP Worldwide, more than 1,200 clinical trials across the globe were disrupted by June 2020.
The impact varied due to changes in COVID-19 case volumes throughout the year, but the worst effect was seen in April 2020. Trials involving respiratory disease, oncology, ID/anti-infectives, and cardiovascular disease were the worst-hit during this time.
The increase in pharmaceutical R&D has resulted in a sharp increase in the number of cell & gene therapy candidates under development. This has made it necessary to outsource manufacturing services to develop cost-effective and efficient cell & gene therapies.
The trend suggests that the top pharma companies are increasing their R&D efficiencies through heavy R&D investments to see returns on their investment in the long run and through collaborative R&D efforts. According to an EvaluatePharma report, the worldwide pharmaceutical R&D spending was valued at USD 136 billion in 2012; this increased to USD 186 billion in 2019.
Currently, there are 1,200 cell & gene therapies in trials worldwide. There are more than 700 investigational cell & gene therapies in clinical development in the US alone. However, manufacturing facilities have not kept up. It has been estimated that hundreds of facilities will be needed to manufacture the treatments that are now in clinical trials.
In 2020, cell therapy segment dominated the cell & gene therapy manufacturing services market. This can be attributed to the advent of new technologies and innovative products that have enabled several variety of cells such as hematopoietic stem cells (HSC), mesenchymal stem cells, natural killer cells, dendritic cells, and T-cells to treat diseases and conditions.
